Company news

Mesoblast Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GVHD Day 28 Results Presentation

February 22, 2018

Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial

February 21, 2018

Appendix 3B with prospectus

January 19, 2018

Mesoblast Receives RMAT For LVAD Heart Failure Patients

December 21, 2017

Mesoblasts P3 GVHD Trial Completes Enrollment

December 19, 2017

Mesoblast Grants TiGenix License For Treatment of Fistulae

December 14, 2017

MSB Named Global Technology Leader In Cell Therapy Industry

December 7, 2017

Response to ASX Aware Letter Query

November 16, 2017

Mesoblast Provides Corporate Update and Q1 Financial Results

November 14, 2017

RA Phase 2 Trial Results Presented At ACR Annual Meeting

November 12, 2017

End-Stage Heart Failure Trial Completes Enrollment

September 27, 2017

Mesoblast Corporate Updates at Healthcare Conferences

September 25, 2017

Retail Entitlement Offer

August 31, 2017

Underwritten A$50.7M Raise Closes Institutional Allocation

August 29, 2017

Fully Underwritten A$50.7 Million Entitlement Offer

August 25, 2017

Potential For Accelerated Market Entry In Advanced CHF

August 23, 2017

Positive Results of MSB Therapy in Osteoarthritis Published

August 16, 2017

Mesoblast RA Results Presented At EULAR Congress

June 22, 2017

MSB Provides Q3 Operational Highlights and Financial Results

May 24, 2017

Third Quarter Financial Results On Form 6-K

May 24, 2017

Successful Interim Analysis in Phase 3 Heart Failure Trial

April 9, 2017

Mesoblast Receives A$3.7m From Aus Govt For R&D

April 5, 2017

FDA Clears Heart Disease Trial At Boston Childrens Hospital

April 3, 2017

Process Initiated For CHF P3 Interim Analysis

March 30, 2017

Mesoblast Raises US$40 Million

March 26, 2017

Durable Three Year Outcomes in Disc Disease

March 15, 2017

FDA Grants Mesoblast Fast Track Designation For GVHD

March 6, 2017

Positive Nine Month RA Results For Mesoblast Cell Therapy

February 15, 2017

Published Results Show MSB Cells Effective In RA Model

February 13, 2017

Mesoblast Director Recognized For Cardiovascular Leadership

January 30, 2017

Mesoblast And Mallinckrodt Enter Into Agreement

December 22, 2016

MD Anderson and NIH Fund Trial Using Mesoblast Technologies

December 6, 2016

First Quarter Results On Form 6K

November 14, 2016

Successful Interim Futility Analysis In P3 Trial for GVHD

November 13, 2016

MSB Japan Strategy Highlighted At Business Council Meeting

October 12, 2016

Mesoblast Phase 2 Diabetic Kidney Disease Results Published

October 6, 2016

Preliminary Final Report (Including Appendix 4E)

August 24, 2016

MSB Strengthens US Patent Portfolio For Rheumatic Diseases

August 16, 2016

Mesoblast P2 Results Show Dose-Related Improvements In RA

August 8, 2016

MSB Back Pain Results Presented, Receive Best Science Award

August 1, 2016

Update on Heart Failure Trial and Funding of Operations

July 1, 2016

Update on Global Heart Failure Program

June 13, 2016

Suspension from Official Quotation

June 3, 2016

Mesoblast Receives $6.2m From Aus Govt For R&D

May 20, 2016

Mesoblast Provides Q3 Financial Results and Corporate Update

May 9, 2016

Mesoblast Cells Show Disease Modifying Effects on Knee OA

March 31, 2016

MSB partner jcr files for product approval

March 30, 2016

Market Exclusivity Strengthened by New USA Healthcare Act

March 30, 2016

Key Bone Repair Patent Granted in the United States

March 30, 2016

TGA Approval To Commercially Manufacture Stem Cell Products

March 30, 2016

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 105 decks. Every deck is listed under its year.